Core Viewpoint - Grail, Inc. experienced a significant decline in market value, losing approximately 50% after the NHS Galleri randomized trial failed to meet its primary endpoint [1] Financial Guidance and Market Reaction - Grail's forward guidance during the Class Period may have omitted known challenges that were material to investors [2] - CEO Robert P. Ragusa indicated on the Q3 2025 earnings call that the company's cash runway extends into 2030, with a cash-burn guidance of no more than $290 million for the full year of 2025 [2] - The guidance provided did not consider scenarios where the NHS trial missed its primary endpoint, which was disclosed in February 2026, leading to the stock's 50% drop [3]